Nilotinib cardiac toxicity: Should we still be concerned?

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 577-578

  Atallah, Ehab ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; CASPASE 7; DASATINIB; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IMATINIB; LACTATE DEHYDROGENASE; NILOTINIB; PLACEBO; X BOX BINDING PROTEIN 1;

APOPTOSIS; CARDIOTOXICITY; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; DRUG CYTOTOXICITY; EDITORIAL; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEART DISEASES; HUMANS; MICE; MYOCYTES, CARDIAC; PATIENT SELECTION; PYRIMIDINES; RATS; RETROSPECTIVE STUDIES;

EID: 79954594715     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.021     Document Type: Editorial

References (7)

1. Freebern W.J., Fang H.S., Slade M.D., Wells S., Canale J., Megill J., et al. In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: dasatinib, imatinib and nilotinib. ASH Annual Meeting Abstacts, vol. 110 2007, 4582.
2. Wolf A., Couttet P., Dong M., Grenet O., Heron M., Junker U., et al. Preclinical evaluation of potential nilotinib cardiotoxicity. Leuk Res 2011, 35:631-637.
3. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz JA, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27;117(4):1141-5. Epub 2010 Nov 22.
4. Larson RA, Hochhaus A, Saglio G, Rosti G, Lopez JL, Stenke L, et al. Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd. ASH Annual Meeting Abstracts 2010;116:2291.
5. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
6. Wolf A., Couttet P., Dong M., Grenet O., Heron M., Junker U., et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res. 2010, 34(9):1180-1188.
7. Atallah E., Durand J.B., Kantarjian H., Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007, 110:1233-1237.